These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 19669256)

  • 41. Cost-effectiveness of entecavir versus lamivudine for the suppression of viral replication in chronic hepatitis B patients in Brazil.
    Costa AM; L 'italien G; Nita ME; Araujo ES
    Braz J Infect Dis; 2008 Oct; 12(5):368-73. PubMed ID: 19219274
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cooled radiofrequency ablation of the genicular nerves for chronic pain due to osteoarthritis of the knee: a cost-effectiveness analysis based on trial data.
    Desai M; Bentley A; Keck WA; Haag T; Taylor RS; Dakin H
    BMC Musculoskelet Disord; 2019 Jun; 20(1):302. PubMed ID: 31238925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China.
    Toy M; Salomon JA; Jiang H; Gui H; Wang H; Wang J; Richardus JH; Xie Q
    Hepatology; 2014 Jul; 60(1):46-55. PubMed ID: 24990105
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada.
    Tian F; Houle SKD; Alsabbagh MW; Wong WWL
    Pharmacoeconomics; 2020 Feb; 38(2):181-192. PubMed ID: 31691902
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Management of viral hepatitis B.
    Pramoolsinsup C
    J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S125-45. PubMed ID: 12000599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
    Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
    JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-effectiveness analysis of interferon-alpha therapy in the treatment of chronic hepatitis B in Taiwan.
    Pwu RF; Chan KA
    J Formos Med Assoc; 2002 Sep; 101(9):632-41. PubMed ID: 12645191
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-Effectiveness and Clinical Impact of Antiviral Strategies of HBeAg-Positive and -Negative Chronic Hepatitis B.
    Oyagüez I; Buti M; Brosa M; Rueda M; Casado MA
    Ann Hepatol; 2017; 16(3):358-365. PubMed ID: 28425405
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis.
    Oliveira GL; Almeida AM; Silva AL; Brandão CM; Andrade EI; Cherchiglia ML; Acurcio Fde A
    Rev Saude Publica; 2013 Aug; 47(4):769-78; discussion 779. PubMed ID: 24346678
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The long-term cost effectiveness of treatments for benign prostatic hyperplasia.
    DiSantostefano RL; Biddle AK; Lavelle JP
    Pharmacoeconomics; 2006; 24(2):171-91. PubMed ID: 16460137
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis.
    Kanwal F; Farid M; Martin P; Chen G; Gralnek IM; Dulai GS; Spiegel BM
    Am J Gastroenterol; 2006 Sep; 101(9):2076-89. PubMed ID: 16968510
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis.
    Veenstra DL; Spackman DE; Di Bisceglie A; Kowdley KV; Gish RG
    Aliment Pharmacol Ther; 2008 Jun; 27(12):1240-52. PubMed ID: 18373637
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of chronic hepatitis B: Evolution over two decades.
    Yuen MF; Lai CL
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():138-43. PubMed ID: 21199525
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness analysis of antiviral treatments for HBeAg-positive chronic hepatitis B in Canada.
    He J; Bowen JM; Xie F; Goeree R
    Value Health; 2012; 15(6):894-906. PubMed ID: 22999140
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data.
    Crowley S; Tognarini D; Desmond P; Lees M; Saal G
    J Gastroenterol Hepatol; 2002 Feb; 17(2):153-64. PubMed ID: 11966945
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
    Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
    Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The cost-effectiveness of alternative therapeutic strategies for the management of chronic hepatitis B in Poland.
    Orlewska E
    Value Health; 2002; 5(5):405-21. PubMed ID: 12201858
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.